Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112186Source: DataRank Database

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity is a research paper published in European Journal of Medicinal Chemistry (2020). On theSindex it has a DataRank of 0. It has been cited 115 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access115 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 5.17)OA: greenTopics (55)Linked Datasets (3)DataCite Reuse (3)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Dinesh Thummuri ORCID,Xingui Liu ORCID,Wanyi Hu,Peiyi Zhang ORCID,Sajid Khan ORCID

Live enrichment

PubMed:32145645 PMC:PMC7433031 OpenAlex:https://openalex.org/W3006981712

NCI NIH HHS

Grant: R21 CA223371

NCI NIH HHS

Grant: R01 CA211963

NCI NIH HHS

Grant: R01 CA219836

National Cancer Institute

FWCI

5.17

Citation Percentile

1.0%

Influential Citations

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7433031

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433031

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7433031

publisherhttps://api.elsevier.com/content/article/PII:S0223523420301537?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0223523420301537?httpAccept=text/plain

Fields of Study

Protein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathwaysMedicineChemistryAniline CompoundsAntineoplastic AgentsBlood PlateletsCell ProliferationCell SurvivalCrystallography, X-RayDose-Response Relationship, DrugDrug DiscoveryDrug Screening Assays, AntitumorHumansModels, MolecularMolecular StructureProteolysisStructure-Activity RelationshipSulfonamidesTumor Cells, Culturedbcl-X Protein

MeSH Terms

Aniline CompoundsAntineoplastic AgentsBlood PlateletsCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansModels, MolecularStructure-Activity RelationshipSulfonamidesTumor Cells, CulturedMolecular StructureCrystallography, X-RayCell Proliferationbcl-X ProteinDrug DiscoveryProteolysis

Keywords

ChemistryPlateletCancer cellBcl-xLToxicityPharmacologyCancer researchCancerApoptosisProgrammed cell deathBiochemistryBiologyImmunologyDegradationBcl-x(l)Protac

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

10.6084/m9.figshare.19327084.v2figshare

Additional file 1 of BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

10.6084/m9.figshare.19327084.v1figshare

Additional file 1 of BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

10.6084/m9.figshare.19327084figshare